The COX-2 expression (3.4%, 1 out of 29 cases) in this study confirms the assertion that COX-2 is a marker of progression in the adenoma-carcinoma spectrum, but it is relatively lower than other studies. This evidence concerns the gene PTGS2 and adenoma.